Aytu BioPharma (NASDAQ:AYTU) Price Target Raised to $13.00

Aytu BioPharma (NASDAQ:AYTU) had its target price raised by investment analysts at Ascendiant Capital Markets from $12.50 to $13.00 in a report released on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Ascendiant Capital Markets’ target price would suggest a potential upside of 477.78% from the stock’s current price.

Several other equities analysts have also weighed in on the company. Wall Street Zen lowered Aytu BioPharma from a “buy” rating to a “hold” rating in a report on Friday, September 26th. Maxim Group dropped their price target on Aytu BioPharma from $9.00 to $7.00 and set a “buy” rating on the stock in a research report on Thursday, September 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Tuesday, October 14th. Finally, Zacks Research upgraded Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research note on Monday, November 24th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $9.33.

Aytu BioPharma Stock Performance

Shares of AYTU opened at $2.25 on Wednesday. The firm has a market capitalization of $22.93 million, a P/E ratio of -0.74 and a beta of 0.28. Aytu BioPharma has a 52 week low of $0.95 and a 52 week high of $2.82. The stock has a 50 day moving average price of $2.17 and a two-hundred day moving average price of $2.19. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.08 and a current ratio of 1.23.

Aytu BioPharma (NASDAQ:AYTU) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.02). The firm had revenue of $13.89 million during the quarter, compared to analysts’ expectations of $17.92 million. Aytu BioPharma had a negative net margin of 20.52% and a positive return on equity of 17.86%.

Hedge Funds Weigh In On Aytu BioPharma

A number of hedge funds and other institutional investors have recently modified their holdings of AYTU. Dimensional Fund Advisors LP purchased a new position in Aytu BioPharma in the 3rd quarter worth $58,000. Two Sigma Investments LP grew its stake in shares of Aytu BioPharma by 96.2% during the third quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock valued at $129,000 after buying an additional 33,701 shares during the last quarter. FNY Investment Advisers LLC purchased a new position in shares of Aytu BioPharma in the second quarter worth about $78,000. Stonepine Capital Management LLC increased its holdings in shares of Aytu BioPharma by 13.8% in the first quarter. Stonepine Capital Management LLC now owns 463,721 shares of the company’s stock worth $556,000 after buying an additional 56,172 shares during the period. Finally, Persistent Asset Partners Ltd bought a new stake in shares of Aytu BioPharma in the 3rd quarter valued at about $117,000. 33.49% of the stock is currently owned by hedge funds and other institutional investors.

Aytu BioPharma Company Profile

Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.